Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study

Journal of Drugs in Dermatology, March-April, 2005 by A. Shalita, B. Miller, A. Menter, W. Abramovits, K. Loven, L. Kakita

Disclosure: Dr. Shalita has been a consultant and investigator for Allergan, Inc., and an advisory board member and investigator for Galderma Laboratories, LP. Dr Miller has received research support from, and been a speaker and consultant for, Allergan, Inc. Drs. Menter and Abramovits have received research support from, and been speakers and consultants for, Allergan, Inc., and Galderma Laboratories, LP. Dr. Loven has been an investigator and speaker for Allergan, Inc., and an investigator for Galderma Laboratories, LP. Dr. Kakita has no financial disclosures or conflicts of interest.

References

1. Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001; 67(6 Suppl):4-9.

2. Leyden JJ, Tanghetti EA, Miller B, et al. Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis. 2002; 69(2 Suppl):12-19.

3. Webster GF, Guenther L, Poulin YP, et al. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002; 69(2 Suppl):4-11.

4. Thiboutot D, Gold MH, Jarratt MT, et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis. 2001; 68(4 Suppl):10-19.

5. Nyirady J, Grossman RM, Nighland M, et al. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris. J Dermatolog Treat. 2001;12(3):149-57.

6. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 1998;139 Suppl 52:48-56.

7. Grosshans E, Marks R, Mascaro JM, et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol. 1998; 139 Suppl 52:26-33.

8. Alirezai M, Meynadier J, Jablonska S, et al. Comparative study of the efficacy and tolerability of 0.1 and 0.03 p. 100 adapalene gel and 0.025 p. 100 tretinoin gel in the treatment of acne. Ann Dermatol Venereol. 1996;123:165-70. [French]

9. Leyden JJ, Grove G, Zerweck C. Facial tolerability of topical retinoid therapy. J Drugs Dermatol. 2004;3(6):641-651.

A. Shalita MD, (a) B. Miller MD, (b) A. Menter MD, (c) W. Abramovits MD, (c) K. Loven MD, (d) L. Kakita MD (e)

a. Department of Dermatology, State University of New York Downstate Medical Center, Brooklyn, NY

b. Oregon Medical Research Center, Portland, OR

c. Division of Dermatology, Baylor University Medical Center, Dallas, TX

d. Rivergate Dermatology & Skin Care Center, Goodlettsville, TN